Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial

作者
Erin Johansson,John P.H. Wilding,Navneet Upadhyay,Naomi van Hest,Myles Kirk,Erik Spaepen,Sarah Zimner‐Rapuch,Lieven Annemans,Harold Edward Bays
出处
期刊: [Figshare (United Kingdom)]
标识
DOI:10.6084/m9.figshare.32065570
摘要

This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity. The analysis focused on individuals with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥27 to <30 kg/m2 + ≥1 obesity-related complication), using data from the head-to-head Phase-3 SURMOUNT-5 trial (patients without type 2 diabetes [T2D]). This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population. The modeled population were at risk of developing obesity-related complications including cardiovascular disease (CVD) and obstructive sleep apnea (OSA), amongst others. These outcomes were modeled using cardiometabolic parameters including weight, systolic blood pressure, high-density lipoprotein, glycated hemoglobin (HbA1c) and total cholesterol, by assessing their impact on healthcare and wider societal costs, quality of life, and mortality. Incremental cost-effectiveness ratios (ICERs; cost/quality-adjusted life year [QALY]) and incremental net health benefit (iNHBs) were calculated, and uncertainty was assessed through sensitivity and scenario analyses. Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide. The model predicted that per 1,000 patients, 70 fewer patients will develop T2D, 10 fewer will develop CVD with tirzepatide (MTD) and patients spend 3.07 more years living with moderate/severe OSA when treated with semaglutide (MTD). Based on this simulation model, using head-to-head SURMOUNT-5 trial data, tirzepatide (MTD) had lower total costs and higher QALYs compared to semaglutide (MTD). This supports that tirzepatide (MTD) is a cost-effective treatment option for individuals with obesity or overweight compared to semaglutide (MTD). This study focused on evaluating the cost-effectiveness of two weight management drugs, tirzepatide and semaglutide, for adults in the US who are overweight or have obesity. Using data from the SURMOUNT-5 trial, the analysis showed that tirzepatide was more effective and less costly, providing better weight loss and health benefits compared to semaglutide. The findings revealed that for every 1,000 individuals treated with tirzepatide, there were 70 fewer cases of type 2 diabetes and 10 fewer cases of heart disease compared to those treated with semaglutide. Additionally, patients on semaglutide experienced a longer duration living with moderate or severe sleep apnea. The study highlighted that tirzepatide led to greater improvements in reducing weight and returning blood sugar levels to normal. Over a lifetime, tirzepatide was found to save $41,688 per patient and provide an additional 0.5 quality-adjusted life years (QALYs; a measure that helps compare how much different treatments improve both length and quality of life), emphasizing its advantages both financially and health-wise. Tirzepatide also demonstrated a reduction in absenteeism (when people are not at work because of illness or health problems) and presenteeism (when people are at work but not fully productive because they are unwell), meaning fewer days lost from work compared to semaglutide, thus highlighting productivity benefits. Overall, the research supports that tirzepatide offered a more cost-effective and beneficial treatment option for weight management in the US healthcare context compared to semaglutide.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不知完成签到 ,获得积分10
刚刚
Owen的应助被berg采纳,获得10
刚刚
Hello的应助被山东科技李采纳,获得100
1秒前
1秒前
paddi完成签到,获得积分10
1秒前
英俊的铭的应助被时平谊采纳,获得200
1秒前
1秒前
1秒前
2秒前
子夜歌发布了新的文献求助10
2秒前
阔达新竹完成签到,获得积分10
4秒前
远看寒山发布了新的文献求助30
4秒前
淡然宛凝完成签到 ,获得积分10
4秒前
4秒前
雯雯发布了新的文献求助10
5秒前
phdbio的应助被Haosen采纳,获得10
8秒前
Kiki发布了新的文献求助10
8秒前
10秒前
11秒前
佳期如梦完成签到,获得积分10
11秒前
lilili完成签到,获得积分20
11秒前
12秒前
Maestro_S的应助被zjy147采纳,获得10
13秒前
致远完成签到 ,获得积分10
14秒前
Firsterchao发布了新的文献求助30
15秒前
15秒前
15秒前
zzz发布了新的文献求助10
15秒前
Zz发布了新的文献求助10
16秒前
16秒前
syvshc完成签到,获得积分0
17秒前
bkagyin的应助被Kiki采纳,获得10
17秒前
涛涛完成签到,获得积分10
18秒前
自觉花生发布了新的文献求助10
18秒前
危险的鲅鱼完成签到 ,获得积分10
19秒前
雯雯完成签到,获得积分10
19秒前
华仔的应助被弗耒earth采纳,获得10
19秒前
cliche完成签到,获得积分10
19秒前
20秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582